Literature DB >> 25860317

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Francesca Ferretti1, Magnus Gisslen, Paola Cinque, Richard W Price.   

Abstract

CNS infection is a nearly constant facet of systemic CNS infection and is generally well controlled by suppressive systemic antiretroviral therapy (ART). However, there are instances when HIV can be detected in the cerebrospinal fluid (CSF) despite suppression of plasma viruses below the clinical limits of measurement. We review three types of CSF viral escape: asymptomatic, neuro-symptomatic, and secondary. The first, asymptomatic CSF escape, is seemingly benign and characterized by lack of discernable neurological deterioration or subsequent CNS disease progression. Neuro-symptomatic CSF escape is an uncommon, but important, entity characterized by new or progressive CNS disease that is critical to recognize clinically because of its management implications. Finally, secondary CSF escape, which may be even more uncommon, is defined by an increase of CSF HIV replication in association with a concomitant non-HIV infection, as a consequence of the local inflammatory response. Understanding these CSF escape settings not only is important for clinical diagnosis and management but also may provide insight into the CNS HIV reservoir.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25860317     DOI: 10.1007/s11904-015-0267-7

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  73 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions.

Authors:  Michael G Worthington; John J Ross
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

3.  Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load.

Authors:  Armelle Pasquet; Faiza Ajana; Hugues Melliez; Caius Giurca; Julien Poissy; Yazdan Yazdanpanah
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

4.  HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects.

Authors:  S G Parisi; C Andreoni; L Sarmati; C Boldrin; A R Buonomini; S Andreis; R Scaggiante; M Cruciani; O Bosco; V Manfrin; G d'Ettorre; C Mengoli; V Vullo; G Palù; M Andreoni
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

5.  HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy.

Authors:  María del Palacio Tamarit; Carmen Quereda; Marta Gonzalez-Rozas; Iñigo Corral; José L Casado
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-21       Impact factor: 2.205

6.  Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

Authors:  Christine Katlama; Marc A Valantin; Michele Algarte-Genin; Claudine Duvivier; Sidonie Lambert-Niclot; Pierre M Girard; Jean M Molina; Bruno Hoen; Sophie Pakianather; Gilles Peytavin; Anne G Marcelin; Philippe Flandre
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

7.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

8.  Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.

Authors:  S F L van Lelyveld; M Nijhuis; F Baatz; I Wilting; W M van den Bergh; M Kurowski; D de Jong; A I M Hoepelman; A M J Wensing
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy.

Authors:  Miriam Estébanez; Natalia Stella-Ascariz; Jesús Mingorance; Ignacio Pérez-Valero; Alicia González-Baeza; Carmen Bayón; Botond Lakatos; Alberto Borobia; Francisco Arnalich; José R Arribas
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-01       Impact factor: 3.731

10.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

View more
  48 in total

1.  Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Authors:  Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.

Authors:  Serena Spudich; Kevin R Robertson; Ronald J Bosch; Rajesh T Gandhi; Joshua C Cyktor; Hanna Mar; Bernard J Macatangay; Christina M Lalama; Charles Rinaldo; Ann C Collier; Catherine Godfrey; Joseph J Eron; Deborah McMahon; Jana L Jacobs; Dianna Koontz; Evelyn Hogg; Alyssa Vecchio; John W Mellors
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

3.  Psychosis of dual origin in HIV infection: Viral escape syndrome and autoimmune encephalitis.

Authors:  David Anguizola-Tamayo; Jone Bocos-Portillo; Lara Pardina-Vilella; Aida Rodriguez-Sainz; Iñigo Vicente-Olabarria; Eduardo Martínez; Marian Gomez-Beldarrain; Juan Carlos Garcia-Monco
Journal:  Neurol Clin Pract       Date:  2019-04

4.  Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?

Authors:  Magnus Gisslén; Peter W Hunt
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

Review 5.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

6.  Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics.

Authors:  Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-09-07       Impact factor: 2.643

7.  Inflammatory flaccid myelitis in a patient with both anti-CRMP-5 IgG and CNS HIV escape.

Authors:  Rajan P Arora; Andrew K Treister; Maile Y Karris; Ronald J Ellis
Journal:  BMJ Case Rep       Date:  2019-05-21

8.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

9.  HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.

Authors:  Maximilian Donath; Timo Wolf; Martin Stürmer; Eva Herrmann; Markus Bickel; Pavel Khaykin; Siri Göpel; Peter Gute; Annette Haberl; Philipp de Leuw; Gundolf Schüttfort; Annemarie Berger; Christoph Stephan
Journal:  Med Microbiol Immunol       Date:  2016-07-28       Impact factor: 3.402

Review 10.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.